Neo Ivy Capital Management Tg Therapeutics, Inc. Transaction History

Neo Ivy Capital Management

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 15, 2023	BUY	$15.48 - $35.0 $233,732 - $528,465	15,099 New	15,099 $375,000
Q4 2021 Feb 15, 2022	SELL	$15.2 - $35.51 $79,176 - $184,971	-5,209 Closed	0 $0
Q3 2021 Nov 16, 2021	SELL	$21.78 - $40.45 $54,341 - $100,922	-2,495 Reduced 32.39%	5,209 $101,000
Q2 2021 Aug 16, 2021	BUY	$32.5 - $48.96 $183,137 - $275,889	5,635 Added 272.35%	7,704 $299,000
Q1 2021 Oct 07, 2021	SELL	$41.61 - $54.3 $17,392 - $22,697	-418 Reduced 16.81%	2,069 $100,000
Q4 2020 Feb 16, 2021	SELL	$25.27 - $54.9 $68,759 - $149,382	-2,721 Reduced 52.25%	2,487 $129,000
Q3 2020 Nov 17, 2020	BUY	$18.49 - $27.24 $96,295 - $141,865	5,208 New	5,208 $139,000
Q2 2020 Aug 17, 2020	SELL	$8.9 - $21.84 $46,360 - $113,764	-5,209 Closed	0 $0
Q2 2020 Aug 17, 2020	BUY	$8.9 - $21.84 $46,360 - $113,764	5,209 New	5,209 $101,000

338

88.3M

2.35M

1.7M

Ticker TGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 145,274,000
Market Cap $4.29B
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...

Get notified when there are updates to the investment portfolio of Neo Ivy Capital Management, based on Form 13F filings with the SEC.

Stay updated on Neo Ivy Capital Management with notifications on news.